Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Advanced Solid Tumor; Liver Metastases

Treatments: Drug: AZD2171

Study type: Interventional

Funder types: Industry

Identifiers

NCT00501605

D8480C00001

Details and patient eligibility

About

Single centre recruiting approximately 80 patients who are given a rising single, followed by multiple, ascending oral dose of AZD2171, assessing the safety and tolerability of AZD2171 in patients with solid tumors and metastatic liver disease.

Enrollment: 80 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of written informed consent
• Male/female, 18 yr or over
• WHO status 0-2
• Refractory advanced solid tumor

Exclusion criteria

• Radiotherapy within 4 weeks of starting AZD2171 treatment
• Low haemoglobin level
• Low platelet or neutrophil counts

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)